Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by Tiger86on Feb 24, 2014 2:38pm

142 Views

Post# 22244026

RE:RE:RE:RE:RE:RE:RE:Zenith shares valued at ???

I was going to base my ACB for the Zenith and RVX shares based on my ACB just before the split and allocate 9.1% to Zenith and 90.9% to RVX.

What would happen if you paid less than $1.00 for your original RVX shares? I can't see why you would get a bump up in your ACB to a $1.00 because of the split.

Bullboard Posts

Visionstate set to leverage success in the U.S. market